



Budget 2026-27

This information is accurate as of 12 May 2026.

Pharmaceutical Benefits Scheme new and amended listings

CATEGORY: Health and disability

The Pharmaceutical Benefits Scheme (PBS) provides subsidised access to medicines to Australian residents and overseas visitors from countries under Reciprocal Health Care Agreements.

This measure lists new medicines on the PBS and expands access to others. It will provide better treatment and improved health for Australians.

New and amended listings

From 1 February 2026, new and amended listings include:

- Calcipotriol with betamethasone dipropionate (Wynzora®) for the treatment of chronic stable plaque type psoriasis vulgaris.
- Extension of the current listing of dapagliflozin (Forxiga®) for chronic kidney disease.
- Vanzacaftor with Tezacaftor and with Deutivacaftor (Alyftrek®) for the treatment of cystic fibrosis.

From 1 March 2026, new and amended listings include:

- Ravulizumab (Ultomiris®) for the treatment of generalised myasthenia gravis.
- Glofitamab (Columvi®) for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma.
- IncobotulinumtoxinA (Xeomin®) for the treatment of chronic sialorrhea due to neurological reasons.
- Changes to the circumstances under which Nivolumab (Opdivo®) and Ipilimumab (Yervoy®) are made available to enable their use for advanced and metastatic cancers.

From 1 April 2026, new and amended listings include:

- Givosiran (Givlaari®) for treatment of Acute Hepatic Porphyria.
- Mogamulizumab (Poteligeo®) for the treatment of patients with relapsed or refractory cutaneous T cell lymphoma.
- Repotrectinib (Augtyro™) for the treatment of adult patients with locally advanced (Stage IIIB) or metastatic (Stage IV) c-ROS proto-oncogene 1 (ROS1) positive non-small cell lung cancer.
- Garadacimab (Andembry®) for the prophylaxis of recurrent attacks of hereditary angioedema Types I and II.
- Zilucoplan (Zilbrysq®) for the treatment of generalised myasthenia gravis.
- Risdiplam (Evrysdi®) 5 mg tablet for the treatment of spinal muscular atrophy.

- Pembrolizumab (Keytruda®) for the treatment of resectable locally advanced head and neck squamous cell carcinoma.
- Pembrolizumab (Keytruda®) for adjuvant treatment of patients with renal cell carcinoma
- Elranatamab (Elrexfio®) for the treatment of relapsed or refractory multiple myeloma.
- Durvalumab (Imfinzi®) for the treatment of limited-stage small cell lung cancer.

From 1 May 2026, new and amended listings include:

- Glycopyrronium (Axxidrox®) for the treatment of patients with severe primary axillary hyperhidrosis.

The PBS is managed by the Department of Health, Disability and Ageing and administered by Services Australia.

This measure isn't subject to legislation passing.

Who this measure affects

This affects Australian residents and overseas visitors from countries under Reciprocal Health Care Agreements.

When this starts and finishes

The new and amended PBS listings are effective from the dates stated above and are ongoing.